MLV & Co. Starts Coverage Of DexCom With Buy, $11 PT
In a note out today, MLV & Co. initiated coverage of biotech firm DexCom (Nasdaq: DXCM) with a buy rating and an $11 price target, implying significant upside from where the shares currently trade.
"DexCom, Inc. has proven continuous glucose monitoring technology and strong market share in the large and growing diabetes care market. We think that the Company's lead product, the SEVEN PLUS continuous glucose monitor, is the best device in its class on the market today," MLV said in the note.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.